| Identification | Back Directory | [Name]
N-[4-[(4-Chlorophenyl)Methoxy]-2-pyridinyl]-2,6-difluoro-benzeneacetaMide | [CAS]
1415834-63-7 | [Synonyms]
CPDA inhibitor
N-[4-[(4-Chlorophenyl)Methoxy]-2-pyridinyl]-2,6-difluoro-benzeneacetaMide
Benzeneacetamide, N-[4-[(4-chlorophenyl)methoxy]-2-pyridinyl]-2,6-difluoro- | [Molecular Formula]
C20H15ClF2N2O2 | [MDL Number]
MFCD29472572 | [MOL File]
1415834-63-7.mol | [Molecular Weight]
388.8 |
| Chemical Properties | Back Directory | [Boiling point ]
579.9±50.0 °C(Predicted) | [density ]
1.381±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO: 100mg/mL | [form ]
Solid | [pka]
11.97±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
N-[4-[(4-Chlorophenyl)methoxy]-2-pyridinyl]-2,6-difluoro-benzeneacetamide is identified to be a potent 5'-inositol phosphatase 2 (SHIP2) inhibitor and can enhance in vitro insulin signaling through the Akt(protein kinase B) pathway. | [Biological Activity]
Cell permeable: yes''Primary Target
SHIP2 | [in vivo]
CPDA greatly improves abnormal glucose metabolism in diabetic animals. CPDA improves the abnormal glucose metabolism in db/db mice. |
|
|